Literature DB >> 2189442

Infusion of recombinant human prorenin into rhesus monkeys. Effects on hemodynamics, renin-angiotensin-aldosterone axis and plasma testosterone.

T Lenz1, J E Sealey, R W Lappe, C Carilli, G T Oshiro, J D Baxter, J H Laragh.   

Abstract

Prorenin, the biosynthetic precursor of active renin, is present in high concentrations in the kidney and reproductive organs. We have proposed that prorenin may be the vehicle of local renin systems, separating the functions of circulating and tissue renin. In the present study, we investigated the effect of increasing plasma prorenin 3- to 4-fold by infusing recombinant prorenin, 400 ng/min for 40 min, into male rhesus monkeys. The prorenin was first warmed to 37 degrees C to reduce the endogenous renin activity to a minimum. The study included a 20 min baseline and a 40 min recovery period. Plasma prorenin increased from 72 +/- 14 ng/mL/h to a maximum of 246 +/- 18 ng/mL/h during the infusion (P less than .001) and fell to 169 +/- 23 ng/mL/h 40 min after the infusion was stopped. Active renin did not change significantly. Plasma aldosterone increased slightly during the prorenin infusion (by 13%) and returned to baseline during the recovery period (P less than .05 compared to the infusion period). Plasma testosterone fell significantly from 1.9 +/- 0.1 ng/mL to 1.6 +/- 0.1 ng/mL during the infusion and further to 1.4 +/- 0.1 ng/mL during the post-infusion period (P less than .05). Blood pressure fell slightly but not significantly. Heart rate, glomerular filtration rate and renal blood flow, as well as urine flow and urine sodium and potassium excretion showed no significant change. These results demonstrate that human recombinant prorenin is not converted to active renin in the circulation of rhesus monkeys.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189442     DOI: 10.1093/ajh/3.4.257

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

1.  The zymogen of plasmepsin V from Plasmodium falciparum is enzymatically active.

Authors:  Huogen Xiao; Brian C Bryksa; Prasenjit Bhaumik; Alla Gustchina; Yoshiaki Kiso; Shao Q Yao; Alexander Wlodawer; Rickey Y Yada
Journal:  Mol Biochem Parasitol       Date:  2014-10-25       Impact factor: 1.759

Review 2.  New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II.

Authors:  Jia L Zhuo; Xiao C Li
Journal:  Peptides       Date:  2011-06-14       Impact factor: 3.750

Review 3.  Changes in the renin-angiotensin-aldosterone axis in later life.

Authors:  J Belmin; B I Lévy; J B Michel
Journal:  Drugs Aging       Date:  1994-11       Impact factor: 3.923

4.  Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells.

Authors:  E P Feener; J M Northrup; L P Aiello; G L King
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

Review 5.  The (pro)renin receptor. A decade of research: what have we learned?

Authors:  Manne Krop; Xifeng Lu; A H Jan Danser; Marcel E Meima
Journal:  Pflugers Arch       Date:  2012-04-28       Impact factor: 3.657

6.  (Pro)renin Receptor-Dependent Induction of Profibrotic Factors Is Mediated by COX-2/EP4/NOX-4/Smad Pathway in Collecting Duct Cells.

Authors:  Cristian Reyes-Martinez; Quynh My Nguyen; Modar Kassan; Alexis A Gonzalez
Journal:  Front Pharmacol       Date:  2019-07-23       Impact factor: 5.810

Review 7.  Functional renin receptors in renal mesangial cells.

Authors:  Yufeng Huang; Wayne A Border; Nancy A Noble
Journal:  Curr Hypertens Rep       Date:  2007-04       Impact factor: 4.592

8.  Increased total Renin levels but not Angiotensin-converting enzyme activity in obese patients with polycystic ovary syndrome.

Authors:  Ziynet Alphan; Zehra Berberoglu; Suheyla Gorar; Zehra Candan; Aynur Aktas; Yalcin Aral; Esranur Ademoglu
Journal:  Med Princ Pract       Date:  2013-07-26       Impact factor: 1.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.